Clinical Lymphedema Evaluation - Advancing Reconstruction of Head and Neck Lymphatics With Symani

Exclusion Criteria

• •1. Patient who is incapable and/or unwilling to provide informed consent
• •2. Patients with irreversible head and neck lymphedema, defined as stage 3 of the MD Anderson Cancer Center Head and Neck Lymphedema Rating Scale
• •3. Active systemic infection under treatment with intravenous antibiotics
• •4. Clinically significant cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigator's discretion
• •5. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease
• •6. Currently receiving chemotherapy or radiation therapy (uncontrolled tumor)
• •7. A history of malignancy or cancer treatment within the past 6 months (tumor control)
• •8. Patient with unsatisfactory manual lymphatic drainage and/or compression garments for at least six months
• •9. Patient with prior lymphatic reconstruction in the targeted head \& neck area
• •10. Patient's lymphatic disease is due to lipedema
• •11. Patients with other medical conditions that could result in symptoms which overlap symptoms of lymphedema (e.g., thrombosis in the external or internal jugular vein)
• •12. Current infection in the head \& neck area in which lymphedema is present
• •13. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or outcomes
• •14. Patient is ineligible to participate for other reasons in the judgement of the investigator